Market cap
$31,300 Mln
Revenue (TTM)
$4,539 Mln
P/E Ratio
35.6
P/B Ratio
10.1
Div. Yield
0 %
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
31,300 | 259,154 | 187,950 | 163,332 | 153,768 |
Revenue ($ Mln) |
4,539 | 47,351 | 48,229 | 25,608 | 11,578 |
Net Profit ($ Mln) |
895.00 | 7,083.00 | 4,701.00 | 4,331.00 | 2,957.20 |
Net Margin (%) |
19.72 | 14.96 | 9.75 | 16.91 | 25.54 |
RoE (%) |
30.75 | 13.24 | 9.12 | 8.13 | 17.58 |
Price to Earnings |
35.63 | 36.89 | 40.49 | 38.44 | 53.64 |
Price-To-Book |
10.07 | 4.86 | 3.64 | 3.09 | 9.54 |
Income Statement ($ Mln)
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4,539.00 | 47,351.00 | 48,229.00 | 25,608.00 | 11,578.00 |
|
Cost of Revenue
|
1,440.00 | 27,729.00 | 20,720.00 | 10,603.00 | 3,798.50 |
|
Gross Profit
|
2,893.00 | 18,239.00 | 24,607.00 | 14,970.00 | 6,642.30 |
|
Operating Expenses
|
2,083.00 | 11,106.00 | 20,276.00 | 9,787.00 | 4,495.40 |
|
Operating Profit (EBIT)
|
1,016.00 | 8,515.00 | 7,233.00 | 5,218.00 | 3,284.10 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
1,059.00 | 7,869.00 | 6,562.00 | 4,818.00 | 3,619.00 |
|
Provision for Tax
|
164.00 | 742.00 | 1,861.00 | 487.00 | 645.90 |
|
Profit after Tax (Net Income)
|
895.00 | 7,083.00 | 4,701.00 | 4,331.00 | 2,957.20 |
|
Minority Interest
|
0.00 | -22.00 | 0.00 | 0.00 | -15.90 |
|
Consolidated Profit
|
334.00 | 1,964.00 | 1,776.00 | 1,197.00 | 0.00 |
Liabilities ($ Mln)
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
3,145.00 | 54,762.00 | 51,027.00 | 53,621.00 | 15,986.20 |
|
Minority Interest
|
0.00 | -22.00 | 0.00 | 0.00 | -15.90 |
|
Non-Current Liabilities
|
2,511.00 | 45,295.00 | 40,472.00 | 30,610.00 | 698.30 |
|
Current Liabilities
|
1,156.00 | 14,170.00 | 16,152.00 | 9,050.00 | 2,533.00 |
|
Total Liabilities
|
6,644.00 | 110,343.00 | 86,713.00 | 83,464.00 | 20,458.70 |
Assets ($ Mln)
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
3,777.00 | 88,618.00 | 84,751.00 | 78,494.00 | 10,920.80 |
|
Current Assets
|
3,035.00 | 25,615.00 | 23,496.00 | 14,787.00 | 8,428.30 |
|
Total Assets
|
6,644.00 | 110,343.00 | 86,713.00 | 83,464.00 | 20,458.70 |
|
Total Debt*
|
2,313.00 | 41,370.00 | 31,159.00 | 26,482.00 | 0.00 |
|
Net Current Assets
|
1,879.00 | 11,445.00 | 7,344.00 | 5,737.00 | 5,895.30 |
Cashflow ($ Mln)
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,079.00 | 7,818.00 | 9,566.00 | 6,416.00 | 3,030.50 |
|
Cash Flow from Investing Activities
|
-55.00 | -4,047.00 | -2,422.00 | -1,196.00 | 665.80 |
|
Cash from Financing Activities
|
-744.00 | 1,801.00 | -6,309.00 | -2,961.00 | -2,364.10 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
16.55 | 7.69 | 10.03 | 5.25 | 16.46 |
|
ROE (%)
|
30.75 | 13.24 | 9.12 | 8.13 | 17.58 |
|
ROA (%)
|
11.11 | 5.75 | 4.21 | 4.59 | 13.74 |
|
EBIT Margin (%)
|
24.43 | 18.92 | 15.09 | 20.22 | 33.80 |
|
Net Margin (%)
|
19.72 | 14.96 | 9.75 | 16.91 | 25.54 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
5.93 | 8.27 | 10.00 | 5.52 | 20.45 |
|
EBIT Growth (%)
|
11.46 | 4.98 | -15.99 | 16.46 | 23.61 |
|
Net Profit Growth (%)
|
27.31 | 7.81 | -66.37 | 23.64 | 7.66 |
|
EPS Growth (%)
|
30.40 | 9.68 | -66.31 | 26.16 | 9.30 |
|
Book Value Growth (%)
|
32.09 | 9.36 | 0.78 | 6.02 | -2.83 |
Valuation Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
23.76 | 32.43 | 33.55 | 45.04 | 71.47 |
|
Price / Book Value
|
7.42 | 4.09 | 4.20 | 3.10 | 11.45 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
14.49 | 21.61 | 18.87 | 25.42 | 49.76 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.57 | 0.71 | 0.58 | 0.45 | 0.00 |
|
Short term debt to equity ratio
|
0.03 | 0.04 | 0.03 | 0.04 | 0.00 |
|
Current Ratio
|
2.63 | 1.81 | 1.45 | 1.63 | 3.33 |
|
Quick Ratio
|
2.05 | 1.41 | 1.00 | 1.29 | 2.49 |
|
Interest Coverage
|
15.31 | 6.12 | 7.96 | 14.38 | -- |
Operating Efficiency Ratios
| Illumina (ILMN) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Danaher (DHR) | Intuitive Surgical (ISRG) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
16.26 | 20.33 | 18.73 | 20.02 | 14.87 |
|
Asset Turnover
|
0.56 | 0.38 | 0.43 | 0.27 | 0.54 |
|
Receivable days
|
67.57 | 82.76 | 61.20 | 61.72 | 54.16 |
|
Inventory Days
|
140.41 | 72.19 | 117.44 | 91.69 | 177.54 |
|
Payable days
|
58.26 | 46.50 | 78.11 | 68.44 | 23.93 |
|
Cash Conversion Cycle
|
149.72 | 108.45 | 100.53 | 84.97 | 207.78 |